» Articles » PMID: 38719336

Comprehensive Single-cell Analysis Deciphered Microenvironmental Dynamics and Immune Regulator Olfactomedin 4 in Pathogenesis of Gallbladder Cancer

Abstract

Objective: Elucidating complex ecosystems and molecular features of gallbladder cancer (GBC) and benign gallbladder diseases is pivotal to proactive cancer prevention and optimal therapeutic intervention.

Design: We performed single-cell transcriptome analysis on 230 737 cells from 15 GBCs, 4 cholecystitis samples, 3 gallbladder polyps, 5 gallbladder adenomas and 16 adjacent normal tissues. Findings were validated through large-scale histological assays, digital spatial profiler multiplexed immunofluorescence (GeoMx), etc. Further molecular mechanism was demonstrated with and studies.

Results: The cell atlas unveiled an altered immune landscape across different pathological states of gallbladder diseases. GBC featured a more suppressive immune microenvironment with distinct T-cell proliferation patterns and macrophage attributions in different GBC subtypes. Notably, mutual exclusivity between stromal and immune cells was identified and remarkable stromal ecosystem (SC) heterogeneity during GBC progression was unveiled. Specifically, SC1 demonstrated active interaction between Fibro-iCAF and Endo-Tip cells, correlating with poor prognosis. Moreover, epithelium genetic variations within adenocarcinoma (AC) indicated an evolutionary similarity between adenoma and AC. Importantly, our study identified elevated olfactomedin 4 (OLFM4) in epithelial cells as a central player in GBC progression. OLFM4 was related to T-cell malfunction and tumour-associated macrophage infiltration, leading to a worse prognosis in GBC. Further investigations revealed that OLFM4 upregulated programmed death-ligand 1 (PD-L1) expression through the MAPK-AP1 axis, facilitating tumour cell immune evasion.

Conclusion: These findings offer a valuable resource for understanding the pathogenesis of gallbladder diseases and indicate OLFM4 as a potential biomarker and therapeutic target for GBC.

Citing Articles

Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies.

Ao J, Hu M, Wang J, Jiang X Front Immunol. 2025; 16:1559465.

PMID: 40013133 PMC: 11862832. DOI: 10.3389/fimmu.2025.1559465.


Progress in understanding the regulatory mechanisms of immune checkpoint proteins PD-1 and PD-L1 expression.

Wu X, Zhu Z, Zhang J, Tian M, Zhao P Clin Transl Oncol. 2025; .

PMID: 39776397 DOI: 10.1007/s12094-024-03835-4.


PTBP3 Mediates IL-18 Exon Skipping to Promote Immune Escape in Gallbladder Cancer.

Zhao C, Zhao J, Zhang Y, Zhu Y, Yang Z, Liu S Adv Sci (Weinh). 2024; 11(38):e2406633.

PMID: 39116343 PMC: 11481411. DOI: 10.1002/advs.202406633.


Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer.

Ni L, Xu J, Li Q, Ge X, Wang F, Deng X Cancer Manag Res. 2024; 16:941-963.

PMID: 39099760 PMC: 11296367. DOI: 10.2147/CMAR.S474348.

References
1.
Kotliar D, Veres A, Nagy M, Tabrizi S, Hodis E, Melton D . Identifying gene expression programs of cell-type identity and cellular activity with single-cell RNA-Seq. Elife. 2019; 8. PMC: 6639075. DOI: 10.7554/eLife.43803. View

2.
Lazcano-Ponce E, Miquel J, Munoz N, Herrero R, Ferrecio C, Wistuba I . Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2002; 51(6):349-64. DOI: 10.3322/canjclin.51.6.349. View

3.
Ramanathan R, Belani C, Singh D, Tanaka M, Lenz H, Yen Y . A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009; 64(4):777-83. DOI: 10.1007/s00280-009-0927-7. View

4.
Nepal C, Zhu B, ORourke C, Bhatt D, Lee D, Song L . Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. J Hepatol. 2020; 74(5):1132-1144. PMC: 8058239. DOI: 10.1016/j.jhep.2020.11.033. View

5.
Hemminki K, Forsti A, Hemminki O, Liska V, Hemminki A . Long-term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast. Int J Cancer. 2022; 151(2):200-208. DOI: 10.1002/ijc.33980. View